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artifacts. Since a previous literature review by San Martin-Rodriguez et al. in 2005,
many more studies have examined organizational determinants, yet studies re-
garding systematic factors, such as health care systems, remain scarce.
CONCLUSIONS: Interprofessional collaboration is influenced by systematic, orga-
nizational, and interactional factors. Policies targeting multi-level aspects may be
helpful in enhancing interprofessional collaboration and ultimately improving pa-
tient care. Future studies are needed to examine factors beyond the interactional
level and their relationships with patient outcomes.
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THE CHARACTERISTICS OF CLINICAL TRIALS IN ASIA
Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S
Costello Medical Consulting Ltd., Cambridge, UK
OBJECTIVES: To investigate the characteristics of clinical trials conducted in 5
Asian countries over the past 2 years with a focus on: disease conditions, funding
sources and age groups. METHODS: ClinicalTrials.gov was searched for trials ini-
tiated after January 1, 2010 in the following countries: Indonesia, Korea, Malaysia,
Taiwan and Thailand. The 10 most common conditions and trial sponsors were
ranked and the percentage of trials in adults and children was calculated. These
figures were compared between countries. RESULTS: During the time period, the
following number of trialswere identified (number; trials per 1,000,000 population):
Taiwan (826; 35.6), Korea (1597; 32.7), Thailand (375; 5.4), Malaysia (132; 4.6) and
Indonesia (47; 0.2). The most common trials in all countries were for chronic con-
ditions. Trials on type 2 diabeteswere themost common trials in Taiwan, Thailand,
Malaysia and Indonesia (range: 3-18%), and were the 3rd most common in Korea
(2%). Breast cancer trials were also common in all 5 countries (range: 1-2%) and
non-small cell lung cancer trials were common in 4 countries (range: 1-2%), except
Indonesia. Funding for the trials was predominantly non-industry in Taiwan, Thai-
land and Korea (64%, 61% and 53% respectively), but predominantly industry in
Malaysia and Indonesia (72% and 54% respectively). Over 40% of trials in Taiwan
were sponsored by local medical institutions. Trials in adults alone were the most
common in all countries: Korea (84%),Malaysia (84%), Taiwan (81%), Thailand (74%)
and Indonesia (65%). CONCLUSIONS: The number of trials per 1,000,000 population
was much higher in Taiwan and Korea than in Thailand, Malaysia and Indonesia.
Trials conducted in all these countries, however, show strong similarities in terms
of the conditions studied; although there are some differences (e.g. funding
sources) between the countries that suggest other factors influence clinical trials in
these countries.
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OBJECTIVES: To explore the perceptions of Malaysian community pharmacist to-
wards locally manufactured generic medicines. METHODS: A cross-sectional de-
scriptive study involving entire population (N 270) of practising community phar-
macists in the State of Penang, Malaysia was undertaken using a self-completed
anonymous mail questionnaire. RESULTS: Responses were received from 48 phar-
macists (response rate 17.8%). Majority of the respondents (97.9%) actively dis-
pensed generic medicines in their practice. Only 37.5% of the respondents viewed
locally manufactured generic medicines as equal in quality compared to the im-
ported generics from international manufacturers. Approximately 60% of the re-
spondents, however, agreed that domestic generics are equal in safety and efficacy
as the imported generic medicines. About half of the respondents (47.9%) believed
that imported generic products need to pass more stringent approval process.
Majority of the respondents (68.8%) urged that theMalaysian regulatory authorities
should convince pharmacists about the quality of domestic generic medicines.
CONCLUSIONS: The Malaysian pharmacists have lack of confidence with the ge-
neric medicines produced by local pharmaceutical companies.
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LUNG CANCER TREATMENT: A PARADIGM SHIFT TO TARGETED THERAPIES IN
CLINICAL TRIAL SETTINGS IN ASIA
Gupta J, Gupta P, Kaur H, Jindal R
Heron Health Pvt. Ltd., Chandigarh, India
OBJECTIVES: Lung cancer (LC), the most common cancer in Asia, accounts for
nearly 14.3% of all new cancer incidences and 18.5% of all cancer-related deaths.
Limited treatment options are available in the advanced stages of LC indicating a
high unmet need. The objective of this study was to conduct an assessment of
drugs in development (both off-patent and pipeline) for LC treatment in Asia.
METHODS: Clinicaltrials.gov was searched in February 2012 for randomized con-
trolled trials (Phase II, III, and IV) investigating pharmacologic interventions for LC
in Asia. RESULTS: In total, 137 clinical trials (planned, ongoing, and completed
trials) were identified. Of these, approximately 42% trials have sites only in Asia;
China and/or Taiwan being the major investigational sites. Among these trials, 44
drugs were found to be in pipeline for the treatment of LC. Major progress was
observed in the area of molecular targeted therapies either as monotherapy or in
combinationwith chemotherapy (50%) followed by chemotherapeutic agents (25%)
and immunotherapeutic agents (25%). Majority (59%) of the ongoing phase III trials
are assessing targeted therapies. The key therapeutic classes in assessment in-
clude epidermal growth factor receptor (EGFR)-targeting agents, vascular endothe-
lial growth factor receptor (VEGFR)-targeting agents, protein kinase inhibitors, he-
patocyte growth factor receptor (HGFR) or c-Met inhibitors, and pan-ErbB
inhibitors. Among trials evaluating targeted therapies, EGFR-targeting agents were
being investigated in more than 50% of the trials followed by VEGFR-targeting
agents. CONCLUSIONS: The research focus for the treatment of LC is shifting from
chemotherapies towards the targeted therapies in Asia. Among the targeted ther-
apies, the major focus is on the EGFR-targeting agents.
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OBJECTIVES:Globally, the consideration of subgroup analyses is an emerging topic
in health care evaluation; however, it is unclear towhat extent the consideration of
biomarkers is relevant to Asian health care systems. In particular, the use of bio-
markers is expected to play a large role in cancer treatments, as these are often
expensive and indicated in small populations. The aim of this study was to inves-
tigate how the proportion of cancer trials considering biomarkers in six Asian
countries compared to the USA and the world. METHODS: ClinicalTrials.gov was
searched for all cancer trials that considered the use of biomarkers, by using search
terms such as ‘diagnostic marker’. We assessed the number of trials being carried
out in six Asian countries: Japan, Singapore, Thailand, Malaysia, the Philippines
and Taiwan. The results were compared to all cancer trials conducted in these
countries, in the USA, and globally. RESULTS: Proportions of cancer trials consid-
ering biomarkers differed between the countries assessed, with Taiwan having the
highest percentage of just over 20%,whereasMalaysia andThailandhad the lowest
proportions with 5.2% and 5.4%, respectively. Interestingly, Malaysia and the Phil-
ippines had fewest cancer trials in general, with only 77 and 87 cancer trials having
been conducted in these countries. This compared to 28,414 cancer trials being
conducted worldwide, 3,848 of which (13.5%) considered biomarkers. This propor-
tion was similar in the USA, where 13.1% of cancer trials included some use of
markers. CONCLUSIONS: It is clear that the consideration of biomarkers in cancer
trials is common in the more developed health care markets in Asia such as Sin-
gapore and Taiwan, where proportions of cancer trials taking this into account
were higher than in the USA and globally. Smaller Asianmarkets such asMalaysia,
the Philippines and Thailand appear to lag behind in the trend towards subgroup
analysis.
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OUTCOMES AND FACTORS ASSOCIATED WITH HOSPITAL MORTALITY IN
PATIENTS WITH IMPAIRED LEFT VENTRICULAR FUNCTION UNDERGOING
CORONARY BYPASS GRAFTING; WHERE DO WE STAND?
Furnaz S
Aga Khan University and Hospital, Karachi, Pakistan
OBJECTIVES: To find the hospital mortality andmid term functional improvement
in patients with impaired ventricular function undergoing coronary artery by pass
grafting and identify the risk factors for mortality.METHODS: Retrospective anal-
ysis of preoperative, operative and postoperative variables of patients with im-
paired ventricular function who were operated for isolated first time coronary
artery bypass betweenOctober 2006 toApril 2009.RESULTS:Total 190 patientswith
impaired ventricular function underwent isolated first time coronary artery bypass
grafting during this periodwith amale predominance (82.6%). This constituted 12%
of all coronary artery surgery performed at our institution during this period. Mean
ejection fraction of the group was 25.45.3%. Mean predicted mortality on logistic
Euro scorewas 10.92.7%. Actual in hospitalmortality of the groupwas 4.7%which
is comparable to contemporary published results. Multivariate analysis identified
use of intra aortic balloon pump, non use of internal mammary artery and preop-
erativeNYHA functional class as factors associatedwithmortality.CONCLUSIONS:
Coronary artery bypass grafting can be performed in patients with impaired ven-
tricular function with acceptable hospital mortality and mid term functional im-
provement.
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SATISFACTION ASSESSMENT OF INSURANCE SYSTEM FOR URBAN RESIDENTS
(URMS) OF UNIVERSITY STUDENTS IN SHENYANG
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OBJECTIVES: In the NewChineseMedical Reform, university students are included
into themedical insurance system for urban residents (URMS) from 2010 to resolve
their uninsured status. The current study aimed to evaluate the effect of new
health system from the perspective of the insured students one year after program
implementation. METHODS: Based on the Chinese Customer Satisfaction Index
and review of the literatures, we built a satisfaction evaluation system for URMS of
university students, with one first-level, 7 second-level (Latent variable, xm) and 24
third-level indicators (Explicit variable, yn) to be scored on a five-point Likert-type
scale. After pilot testing and subsequent adjustment, 400 questionnaires were is-
sued to students in 4 universities in NE China. After obtaining the affecting order of
third indexes to their corresponding secondary index through the correlation test,
a Structural Equation Model (SEM) for the satisfaction assessment of URSM was
built basing on the calculated Path coefficient between the xm and yn aftermultiple
linear regressions. Goodness of fit statistics of SEM were used to assess the match
between this model and satisfaction assessment. RESULTS: 393 questionnaires
were returned giving a recovered rate 98.3%. The path coefficients between xm and
yn were: customer trust 1.26, the perceived quality 0.88, customer complaints 0.80,
customer expectations 0.44, public information 0.31, and image of the government
0.29. The satisfaction score of UMRS (29.06 out of 69.75 points) showed very low
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satisfaction level of university students towards the program. CONCLUSIONS: The
results showed the satisfaction assessmentmodelwas suitable to this study. Based
on the order of path coefficients, several reform proposals for improving university
students’ medical insurance are proposed, including establishing a multi-level
medical insurance system with corresponding regulatory and monitoring mecha-
nism of its performance; as well as enhancing awareness and education of stu-
dents about health insurance.
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WORKPLACE-BASED SMOKING CESSATION PROGRAMMES – IDENTIFYING THE
GAPS BETWEEN EVIDENCE AND PRACTICE
Gan HP, Wee HL
National University of Singapore, Singapore, Singapore
OBJECTIVES: Previous research has shown that workplace-based smoking cessa-
tion programme (WPSCP) is cost beneficial to employers due to improved produc-
tivity of employees. Yet, the number of companies in Singapore that support or
provide WPSCP is limited. This study aims to identify gaps between evidence (i.e.
interventions shown to be effective) and practice, which is employers’ perceived
effectiveness and feasibility of interventions for WPSCP. Further, we seek to eval-
uate employers’ willingness to implement specific interventions within their
workplace. METHODS: One to one semi-structured face-to-face interviews with
employers in Singapore were conducted from August till November 2011. Employ-
ers were asked to give their views on what they could do to help their employees
quit smoking. Response options for feasibility and willingness to implement were
yes/ no/ don’t know or unsure. Employers also rated the effectiveness of various
interventions within the workplace as not at all effective/ quite effective/ moder-
ately effective/ very effective/ don’t know or unsure. RESULTS: Representatives
from 40 companies were recruited. Most of the employers rated smoking cessation
talk asmoderately effective (n20, 50%), followed by smoking cessation aids (n16,
40%). The three interventions with themost number of employers judging them as
feasible were smoking cessation posters (n30, 75%), smoking cessation talks
(n29, 72.5%), and contests to help smokers quit (n28, 70%). Majority of the em-
ployers arewilling to disseminate posterswithin theworkplace (n32, 80%) or offer
smoking cessation talks (n31, 77.5%). In contrast, employers did not support
group counseling and pharmacological treatment although they were shown in a
Cochrane review to have strong evidence of efficacy within the workplace.
CONCLUSIONS: Interestingly, interventions shown to be effective in experimental
settings were not supported by employers and they were unwilling to implement
these strategies. This gap between evidence and practice needs to be addressed,
possibly through employer education.
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PERCEPTION ANALYSIS OF PHARMACEUTICAL CARE PRACTICES AMONG
GENERAL PHYSICIANS FROM PART OF SOUTH INDIA
Udupa DN
Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India
OBJECTIVES: To analyse perception of Pharmaceutical Care Practices among Gen-
eral Physicians from Part of South India. METHODS: Study was conducted in Se-
lected Part of South India including Udupi District. Sample size was calculated by
using market research statistical software. Sample size was calculated to achieve
confidence level of research up to 93%. A questionnaire was designed including
closed and open ended questions. Questionnairewas administered to General Phy-
sicians to collect their opinion. Information collected was processed to derive re-
sults and conclusion. RESULTS: Results derived from above study shows that, Gen-
eral Physicians from selected Part of South India are aware about the concept of
Pharmaceutical Care. Majority of respondents are of opinion that Concept of Phar-
maceutical Care is very useful for people to maintain their health. CONCLUSIONS:
Result shows that, there is a need of introduction of Pharmaceutical Care in India.
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OBJECTIVES: : Bipolar disorder is associated with high unemployment rate and
job-related difficulties in small-scaled qualitative, cross-sectional studies and ob-
servational surveys. This study was designed to assess the risk of withdrawal from
labor force in bipolar disorder patients using a national claim-based database in
Taiwan.METHODS: The Psychiatric Inpatients Medical Claims Data (PIMC) dataset
from National Health Insurance Research Database was used and enrolees with a
DSM-IV diagnosis of bipolar disorder (N502) between 1998 and 2001 were
matched with a cohort of controls (N2,008) for comparison. Each patient was
observed since one year before the incidence and up to the end of the 10th year
(12/31/2008). Risks of withdrawal from labor force after adjusting for covariates
were investigated between two groups. RESULTS: The risk of withdrawal from
labor forcewas found higher in patientswith bipolar disorderswith an adjustedHR
of 2.10 (p0.0001), revealing a 110%higher hazard than controls. At one year of time
since the index date, the probability of withdrawal from labor forcewent up greatly
to 47%and 22%, respectively for bipolar disorders and controls and become steadily
increasing ever since. It was 64% and 38%, respectively at the end of the 5th year.
Notably, the probability of withdrawal from labor force were also significantly dif-
ferent even before the incidence (time point: -1 to 0), as 27% and 14% for bipolar
disorders and controls, respectively. The median time of withdrawal from labor
force was 1.39 years (95% CI0.8–2.1) for bipolar patients comparedwith 9.67 years
(95% CI8.71–10.63) for controls (p0.0001). CONCLUSIONS: Bipolar disorders had
an increased risk ofwithdrawal from labor forcewith a longitudinal follow-upup to
10 years using national claimed data in Taiwan.
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USING OBSERVATIONAL COMPARATIVE EFFECTIVENESS STUDIES TO INFORM
DECISION MAKING: THE NEED FOR A TWO-PHASE APPROACH TO ASSESSING
QUALITY AND APPROPRIATENESS
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OBJECTIVES: Observational studies are increasingly being used in comparative
effectiveness research (CER) because they provide information on ‘real-world’ use
of therapies. Most decision makers, however, have little experience in evaluating
observational research. We assessed whether existing standards and scales were
sufficient for identifying observational studies of high enough quality to inform
decision making.METHODS:We identified standards and quality scales for obser-
vational studies published in the peer-reviewed literature or developed by regula-
tory agencies or other organizations. RESULTS: Many standards for observational
studies exist, but most focus on pharmacovigilance or general good research prac-
tices. Very few publications address the use of observational studies for CER, and
only two – the U.S. AHRQ publication, “Registries for Evaluating Patient Outcomes:
A User’s Guide” and the GRACE Checklist – discuss this topic in detail. The AHRQ
registries guide provides a list of criteria to consider when evaluating the quality
and appropriateness of an observational study, many of which are relevant to CER.
The GRACE Checklist is a validated scale to identify observational CER studies with
sufficient quality to inform decision-making. CONCLUSIONS: Few standards and
quality scales are available to assist decision makers in evaluating the quality of
observational CER studies. Once a baseline level of methodological rigor has been
achieved, selecting specific studies to inform decisionmaking is likely to be guided
by nuanced factors related to the specific research question and decision at hand.
Rather than attempting to develop scales or standards that can independently be
used for all types of research questions and decisions, a two-phase approach, in
which a tool like the GRACE Checklist is used to identify studies of sufficient
strength and then a framework is used to select the most appropriate studies for a
specific research question, may be most useful to decision makers.
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THE IMPACT OF THE SURVEILLANCE IN PHARMACOTHERAPY BY HOSPITAL
HEALTH CARE RISKS MANAGEMENT (HHRM)
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OBJECTIVES: Pharmacology is considered as themain basis of medical science and
so the Pharmacotherapy is a valuable therapeutic tool, however adverse drug
events (ADE) are harmful just it may increase the morbidity and mortality, so the
importance of surveillance in all this therapy process. The present study per-
formed by the HHRM aims to point out what are the most common faults that can
lead to ADE and plan improvements to provide greater security and quality in
pharmacotherapy process.METHODS: Active searches fromMay to August of 2011
by HHRM, a multidisciplinary team, in the pharmacotherapeutic process routinely
applied in the ICU and in two clinical and one surgical wards of a public metropol-
itan teaching hospital with about 300 beds, by checking dosages, routes of admin-
istration, correctmedical orders, correct patients, correct devices and possible drug
interactions. RESULTS: There were about 5 big events of pharmacotherapy risks in
a week, with non-compliance in the medical prescriptions of medicine by not
recommended route (15%), wrong solutions for drugs administrations (25%), using
wrong medical devices for drugs administration (10%) and electrolyte abnormali-
ties caused by drugs (50%). There was one administration of wrong drugs in pa-
tients. The method of copy and paste in the medical prescription is a dangerous
process and deserves a big attention CONCLUSIONS: Pharmacotherapy process is
very complex which errors should occurs at various stages, in any different man-
ners and situations, so it needs the support and involvement of every health care
professional and their training in order to ensure greater security and quality in
health care, specially in pharmacotherapy knowledges. So avoiding ADE may re-
duce the time of hospitalization, the cost of treatment, the morbidity and even
mortality. Active searches by HHRM and acting in preventing ADE risks or even
correcting the possible risks is paramount for every health care service.
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OBJECTIVES: The prevailing view in the literature is that additional government
health input has little effect onmortality and/ormorbidity. In China, however, this
is not an accepted consensus. Researchers and policy makers are still debating
whether market or government should take more responsibilities in the health
care area. In this paper, we aim to investigate the efficiency of China public health
spending.METHODS:We obtain unique China provincial level panel data and use
fixed effect model to test the relationship between public health spending and
morbidity rate of thirteen infectious diseases. RESULTS: We find that budgetary
allocation to epidemic prevention and control expenses has little impact on reduc-
ing the morbidity rate of the sample infectious diseases in China. CONCLUSIONS:
Understanding the efficiency of public health spending is crucial in designing pub-
lic health policy in China, especiallywhen the health care system reformenters the
deep water. The above finding suggests that the policy maker should seriously
consider the role of government in the future health care reform.
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